Gyala Therapeutics headquarters details
- City
- Barcelona
- State / region
- Catalunya
- Country
- Spain
- Founded
- 2020
- Website
- gyalatx.com
Location map
Open in Google MapsAll Gyala Therapeutics office locations
| City | State / region | Country | Type |
|---|---|---|---|
| Barcelona HQ | Catalunya | Spain | Headquarters |
Showing the headquarters of 2 recorded locations. See every location in GraphIQ →
About Gyala Therapeutics
Gyala Therapeutics is headquartered in Barcelona, Catalunya, Spain. Founded in 2020, the company has 2 recorded locations and employs approximately 8 people worldwide.
Where is Gyala Therapeutics's main office?
Gyala Therapeutics's main headquarters office is located at Barcelona, Catalunya, Spain. This is the company's primary corporate address.
What does Gyala Therapeutics do?
Gyala Therapeutics is focused on developing new CAR-T therapies for treating hematological malignancies. CAR-T (chimeric antigen receptor T cells) is a type of gene therapy in which T lymphocytes -a type of white blood cells that play a key role in immune responses- are extracted from the patient and modified to attack tumour cells. T lymphocytes are obtained through apheresis (a technique that allows separation of blood components) and genetically reprogrammed with a receptor that binds to a tumor factor. When these cells are transduced back to the patient, they are to specifically recognize tumour cells and attack them. Several types of CAR-T cells have demonstrated efficacy in the treatment of leukemias and B cell lymphomas.
Frequently asked questions
Where is Gyala Therapeutics headquarters?
Gyala Therapeutics's headquarters is located at Barcelona, Catalunya, Spain.
How many offices does Gyala Therapeutics have?
GraphIQ records 2 locations for Gyala Therapeutics, as of October 2026.
When was Gyala Therapeutics founded?
Gyala Therapeutics was founded in 2020 and employs approximately 8 people.
How many employees does Gyala Therapeutics have?
Gyala Therapeutics has approximately 8 employees (GraphIQ estimate, 2026).